Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is among the hidden penny stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) by a whopping 482.3%. Following the purchase of 239,751 shares, the global investment bank now owns 289,461 shares of the company’s stock, valued at approximately $741,000.
Investing in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is like planting a tree; with time and patience, it ought to grow. The biopharmaceutical company develops recombinant therapeutic proteins through its ProCellEx platform, while leveraging its expertise in rare genetic diseases.
Is Telix Pharmaceuticals Limited (TLX) the Best Australian Stock to Buy According to Analysts?
What’s even more interesting is that Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is striving to expand ProCellEx into drug delivery optimization by aiming for particular tissue requirements. This step is what they call a “game-changer” since this system offers what traditional systems lack. From cost efficiency to expressing complex protein capabilities, this platform is poised to lead the future.
Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is a New Jersey-based biopharmaceutical company specializing in recombinant therapeutic proteins. With a commitment to developing innovative plant-based biologics, the company offers Elelyso, Elfabrio, PRX-115, and PRX-119.
While we acknowledge the potential of PLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
[SRC] https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-gains-225033570.html
